<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04711265</url>
  </required_header>
  <id_info>
    <org_study_id>KENYAMRI</org_study_id>
    <nct_id>NCT04711265</nct_id>
  </id_info>
  <brief_title>Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys</brief_title>
  <official_title>A Longitudinal Cohort Study to Assess Sustained Immunogenicity up to 48 Months to Quadrivalent Human Papillomavirus Vaccine Among HIV-infected Girls and Boys Age 10-15 Years in Kenya</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kenya Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kenya Medical Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Longitudinal observational cohort study and extension of the MISP ID: 38406 'immunogenicity&#xD;
      and safety of quadrivalent human papillomavirus vaccine in HIV-infected pre-adolescent girls&#xD;
      and boys in Kenya'.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We evaluated for persistence of HPV antibody by measuring titers to specific HPV types 6, 11,&#xD;
      16 and 18 at re-enrollment month 24 , 36 and 48 months in addition to month 7 and 12, after&#xD;
      initial vaccination. This provided data for immunogenicity among HIV-infected children for&#xD;
      approximately 48 months after initial vaccination. We assessed decline over study intervals&#xD;
      in HPV type-specific antibodies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Actual">January 2019</completion_date>
  <primary_completion_date type="Actual">November 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Human Papillomavirus Antibody Titers</measure>
    <time_frame>48 months</time_frame>
    <description>Geometric mean titers for HPV type -6, -11, -16 and -18</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HIV RNA viral load</measure>
    <time_frame>48 months</time_frame>
    <description>Impact of HIV RNA viral load on HPV antibody response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD 4 cell count</measure>
    <time_frame>48 months</time_frame>
    <description>Impact of immune status on HPV antibody response</description>
  </secondary_outcome>
  <enrollment type="Actual">176</enrollment>
  <condition>HPV Vaccine</condition>
  <condition>HPV Infection</condition>
  <condition>HIV-1-infection</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle Vaccine</intervention_name>
    <description>Intramuscular injection with 3 doses of QHPV</description>
    <other_name>QHPV vaccine</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum samples for HPV antibody titer assessment HIV viral load CD4 cell count&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-1 infected boys and girls who had received 3 doses of QHPV vaccine&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  receipt of 3 doses of QHPV vaccine&#xD;
&#xD;
          -  participated in primary immunogenicity study&#xD;
&#xD;
          -  consent/assent with parental consent for participants age &lt;18 years&#xD;
&#xD;
          -  willing to continue extended follow up for 36 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  decline consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Partners in Health Research and Development</name>
      <address>
        <city>Thika</city>
        <state>Kiambu</state>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 8, 2020</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2021</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kenya Medical Research Institute</investigator_affiliation>
    <investigator_full_name>Nelly Rwamba Mugo</investigator_full_name>
    <investigator_title>Senior Principal Clinical Research Scientist</investigator_title>
  </responsible_party>
  <keyword>HPV Vaccine, HIV infection, Adolescents, Africa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Papillomavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

